Literature DB >> 32714697

Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung Lesions.

Mark E Bernard1, Lana Critchfield1, Mahesh Kudrimoti1.   

Abstract

Our patient is a 48-year-old gentleman who initially was diagnosed with stage IV colorectal cancer on presentation. He had a history of multiple lines of systemic therapy, primary local resection, radioembolization treatments to the liver, along with liver metastasectomy with intraoperative radiofrequency ablation. He initially presented and completed single-isocenter stereotactic body radiation therapy (SBRT) to five right lung metastases with a treatment response and then completed SBRT to two additional right lower lung metastases. Since completion of his SBRT, he has remained disease free. Integration of SBRT to multiple ipsilateral lung lesions achieved a complete clinical response and assisted in keeping him disease free with the support of systemic therapy, and thus improved quality of life.
Copyright © 2020, Bernard et al.

Entities:  

Keywords:  lung; multiple; sbrt

Year:  2020        PMID: 32714697      PMCID: PMC7377660          DOI: 10.7759/cureus.8759

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  5 in total

1.  Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy.

Authors:  R J Klement; J Hoerner-Rieber; S Adebahr; N Andratschke; O Blanck; J Boda-Heggemann; M Duma; M J Eble; H C Eich; M Flentje; S Gerum; P Hass; C Henkenberens; G Hildebrandt; D Imhoff; K H Kahl; N D Klass; R Krempien; F Lohaus; C Petersen; E Schrade; T G Wendt; A Wittig; M Guckenberger
Journal:  Radiother Oncol       Date:  2018-03-03       Impact factor: 6.280

2.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

3.  Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.

Authors:  Hania A Al-Hallaq; Steven Chmura; Joseph K Salama; Kathryn A Winter; Clifford G Robinson; Thomas M Pisansky; Virginia Borges; Jessica R Lowenstein; Susan McNulty; James M Galvin; David S Followill; Robert D Timmerman; Julia R White; Ying Xiao; Martha M Matuszak
Journal:  Pract Radiat Oncol       Date:  2016-05-20

4.  Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Rohann J M Correa; Famke Schneiders; Cornelis J A Haasbeek; George B Rodrigues; Michael Lock; Brian P Yaremko; Glenn S Bauman; Belal Ahmad; Devin Schellenberg; Mitchell Liu; Stewart Gaede; Joanna Laba; Liam Mulroy; Sashendra Senthi; Alexander V Louie; Anand Swaminath; Anthony Chalmers; Andrew Warner; Ben J Slotman; Tanja D de Gruijl; Alison Allan; Suresh Senan
Journal:  BMC Cancer       Date:  2019-08-19       Impact factor: 4.430

5.  Frameless stereotactic body radiation therapy for multiple lung metastases.

Authors:  Qilin Li; Jinming Mu; Wendong Gu; Yuan Chen; Zhonghua Ning; Jianxue Jin; Honglei Pei
Journal:  J Appl Clin Med Phys       Date:  2014-07-08       Impact factor: 2.102

  5 in total
  1 in total

Review 1.  Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases.

Authors:  Enrique Gutiérrez; Irving Sánchez; Omar Díaz; Adrián Valles; Ricardo Balderrama; Jesús Fuentes; Brenda Lara; Cipatli Olimón; Víctor Ruiz; José Rodríguez; Luis H Bayardo; Matthew Chan; Conrad J Villafuerte; Jerusha Padayachee; Alexander Sun
Journal:  Curr Oncol       Date:  2021-07-15       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.